Glaxo sets new transparency policy following fine, Telegraph says Following its recent multi-billion dollar U.S. fines for fraud related to concealing safety issues, GlaxoSmithKline (GSK) said detailed data from its trials would be made available to the scientific community and that an independent panel of experts will review and approve requests for access the data, reported The Telegraph. Reference Link
News For GSK From The Last 14 Days
Check below for free stories on GSK the last two weeks.
Ligand says partner GSK submits application for Promacta Ligand Pharmaceuticals (LGND) said its partner GlaxoSmithKline (GSK) announced today the submission of a supplemental New Drug Application to the FDA for Promacta for the treatment of cytopenias in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.